Partnering with BI Sincerely, Yours - Boehringer Ingelheim
Partnering with BI Sincerely, Yours - Boehringer Ingelheim
Partnering with BI Sincerely, Yours - Boehringer Ingelheim
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Value through Innovation<br />
<strong>Sincerely</strong>, <strong>Yours</strong><br />
<strong>Partnering</strong> <strong>with</strong> <strong>BI</strong>
A strategic intent to partnering,<br />
commercial expertise and unique culture<br />
will underpin our alliance<br />
What is <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
looking for ?<br />
The search for new therapeutic options forms<br />
the cornerstone of research and development<br />
at <strong>Boehringer</strong> <strong>Ingelheim</strong>. We aim to contribute<br />
to therapeutic progress by developing tomorrow’s<br />
cures from today’s science.<br />
For us, partnering is key to success in this mission.<br />
It is central to our company strategy and<br />
forms an integral part of our drug discovery<br />
and development efforts.<br />
Value through Innovation<br />
…the most innovative technologies and therapeutic principles at all stages from<br />
research and development to commercialization.<br />
Content:<br />
• Cardiometabolic Diseases 6<br />
• Central Nervous System 8<br />
• Commercial Opportunities/Other 10<br />
• External Outreach 12<br />
• Immunology/Inflammation 14<br />
• Infectious Diseases 16<br />
• Oncology 18<br />
• Respiratory 20<br />
• Contacts for Asia/Japan 22<br />
• Contacts for Asia/China 24<br />
• Contacts for Strategic Transactions<br />
and Alliance Management 26<br />
2 1<br />
Updated June 2011
Dr. Klaus Wilgenbus<br />
Corporate Sr. Vice President<br />
PM Business Development and Licensing/Strategy<br />
<strong>Ingelheim</strong>, Germany<br />
Phone: +49 6132 77 3094<br />
Fax: +49 6132 77 99200<br />
E-mail: klaus.wilgenbus@boehringer-ingelheim.com<br />
Value through Innovation<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> is looking to the outside world for identifying new product<br />
opportunities in the Prescription Medicines business. We fully appreciate that<br />
excellent ideas are generated by creative minds in the academic and industrial<br />
environment outside <strong>Boehringer</strong> <strong>Ingelheim</strong>.<br />
All of our business development and licensing activities are coordinated through<br />
a well organized global team. It is my pleasure to introduce you to the <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> Business Development and Licensing Team.<br />
Our strategic vision to incorporate innovation through external opportunities is<br />
supported by the Therapeutic Alliances and Strategic Partnerships Team as well as<br />
the Strategic Transactions and Alliance Management Team.<br />
2 3
Dr. BJ Bormann<br />
Head, Therapeutic Alliances and Strategic Partnerships<br />
Ridgefield, CT, USA<br />
Phone: +1 203 798 4547<br />
Fax: +1 203 837 5950<br />
E-mail: bj.bormann@boehringer-ingelheim.com<br />
General Inquiries about Licensing<br />
Value through Innovation<br />
Our vision “Value through Innovation” drives us forward. It helps us to foster value creation<br />
in our company and to look to the future <strong>with</strong> constantly renewed commitment and ambition.<br />
To do so, external partnerships and collaborations at all stages of research, development and<br />
commercialization allow us to strengthen continuously our global franchises in all therapeutic<br />
areas. Close contacts to key players in the biotechnology and pharmaceutical world such as<br />
venture capitalists and other investors are of major importance to us.<br />
4 General Inquiries<br />
5
Dr. Johannes Zanzinger<br />
Global Licensing Cardiometabolic Diseases<br />
Biberach, Germany<br />
Phone: +49 7351 54 4271<br />
Fax: +49 7351 83 4271<br />
E-mail: johannes.zanzinger@boehringer-ingelheim.com<br />
Decades of experience in this therapeutic area allows us to help millions of patients affected by<br />
potentially life-threatening cardiovascular and metabolic diseases. Our research and development<br />
have resulted in major achievements in recent years, especially in thromboembolic<br />
diseases (Dabigatran, Pradaxa®) and <strong>with</strong> our type 2 diabetes programs (Linagliptin/Tradjenta®<br />
(approved by FDA May 2011) and <strong>BI</strong>-10773 in Phase III). Further compounds <strong>with</strong> different<br />
modes of action have also entered clinical development from our diverse portfolio. We are<br />
dedicated to extending this franchise through external partnerships and collaborations at all<br />
stages of development.<br />
Cardiometabolic Diseases<br />
Key Areas for <strong>Partnering</strong><br />
• Atrial fibrillation: complement to our antithrombotic<br />
portfolio<br />
• Diabetes mellitus: differentiated vs.<br />
standard of care and <strong>BI</strong>-portfolio<br />
• Dyslipidemia/hyperlipidemia, and<br />
Atherosclerosis<br />
• Chronic Kidney Disease and Diabetic<br />
complications (focus on Nephropathy,<br />
but retinopathy and neuropathy also<br />
considered)<br />
• Obesity, if weight loss superior to<br />
marketed products can be achieved<br />
• ‘Metabolic Syndrome’ <strong>with</strong> potential<br />
for registration in diabetes and/or<br />
dyslipidemia/atherosclerosis, if additional<br />
effect beyond weight loss can be achieved<br />
• Commercial Opportunities suitable<br />
to expand our own successful<br />
cardiometabolic franchise of established<br />
and new products (e.g. Micardis®,<br />
Metalyse®, Pradaxa®; Tradjenta®)<br />
6 Cardiometabolic Diseases<br />
Excluded areas<br />
• Gene therapy<br />
• Cardiac assist devices; shunts; pacemakers<br />
etc.<br />
7
Dr. Klaus Mendla<br />
Global Licensing CNS<br />
Biberach, Germany<br />
Phone: +49 7351 54 7769<br />
Fax: +49 7351 83 7769<br />
E-mail: klaus.mendla@boehringer-ingelheim.com<br />
Central Nervous System<br />
Diseases of the central nervous system (CNS) are one of our core therapeutic areas. With<br />
Key Areas for <strong>Partnering</strong><br />
the successful launch and marketing of our blockbuster product Sifrol®/ Mirapex® for<br />
Parkinson’s disease and Restless Legs Syndrome, we have underpinned our worldwide<br />
leadership in Neurology.<br />
• Chronic pain:<br />
Orally active compounds <strong>with</strong> a<br />
differentiated pharmacologic profile and<br />
• Neuropsychiatric diseases (including<br />
schizophrenia and depression, and<br />
neuropsychiatric symptoms in Alzheimer’s<br />
We are strongly committed to innovative approaches for the treatment of neurologic and<br />
psychiatric diseases. Our focus is on clearly differentiated products <strong>with</strong> first-in-class or<br />
best-in-class potential.<br />
broad efficacy across different preclinical<br />
models of chronic inflammatory and<br />
neuropathic pain<br />
• Chronic neurodegenerative diseases<br />
(including Alzheimer’s disease and<br />
Parkinson’s disease):<br />
Compounds that target a pathophysiologic<br />
mechanism underlying a range<br />
of neurodegenerative diseases, <strong>with</strong><br />
disease and other dementias):<br />
Agents <strong>with</strong> a novel mechanism of action<br />
that have potential for the treatment<br />
of specific symptoms in a number of<br />
neuropsychiatric diseases<br />
8 Central Nervous System<br />
potential to slow disease progression<br />
9
Dr. Roger Hill<br />
Global Licensing Commercial Opportunities/Other<br />
Ridgefield, CT , USA<br />
Phone: +1 203 798 5137<br />
Fax: +1 203 837 5137<br />
E-mail: roger.hill@boehringer-ingelheim.com<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s development and commercial expertise has resulted in a robust portfolio<br />
of prescription medicines (PM) products in multiple therapeutic areas, and is supported by<br />
global primary care and specialty sales forces (e.g. Spiriva®, Micardis®).<br />
In Commercial Opportunities we seek products and technologies that complement our PM<br />
portfolio as well as unique opportunities that do not fit into our current therapeutic area<br />
strategies. Opportunities of interest include franchise building and life cycle management<br />
for established products, regional deals, and specific solutions for emerging markets and<br />
innovative products that are ready for the market but fall outside of our current therapeutic<br />
area models. Technologies considered include those that can directly impact a portfolio<br />
product such as a companion diagnostic or a compliance technology. In Commercial<br />
Opportunities we also proactively consider strategic out-licensing of R&D projects and<br />
product divestitures.<br />
Commercial Opportunities/Other<br />
Key Areas for Business Development and<br />
<strong>Partnering</strong><br />
Prescription Medicines<br />
• Companion products to support product<br />
portfolio in emerging markets<br />
• New indications outside key TAs listed in<br />
this booklet, for example: Ophthamology<br />
Innovative Healthcare Solutions<br />
• Companion diagnostics<br />
• IT interfaces <strong>with</strong> patient groups<br />
• Compliance technologies<br />
Strategic out-licensing and divestitures<br />
10 Commercial Opportunities/Other<br />
11
Dr. Christine Grygon<br />
Venture Capital Liaison/<strong>BI</strong> Partnership<br />
Ridgefield, CT<br />
Phone: +1 203 798 5651<br />
Fax: +1 203 837 5651<br />
E-mail: christine.grygon@boehringer-ingelheim.com<br />
We believe in the value of building strong relationships <strong>with</strong> traditional and non-traditional<br />
healthcare-related organizations investing in the next wave of therapeutic treatments.<br />
Close contacts to key players in the biotechnology and pharmaceutical world such as venture<br />
capitalists and other investors are of major importance to us. With a dedicated liaison, we<br />
are committed to building close connections to the VC community, investment banking<br />
community, entrepreneurs, incubators and not-for-profit organizations as potential partners<br />
in order to advance innovation toward commercialization and the benefit of patients. We<br />
also seek to connect <strong>with</strong> non-traditional partners such as healthcare providers, managed<br />
care organizations, information technology, contract research and generics companies in<br />
order to understand the ground-breaking technologies these organizations will invest in<br />
to prepare for the future of healthcare.<br />
Through continuing dialog <strong>with</strong> investors, biotech companies, and contacts in the pharmaceutical<br />
business, we monitor trends in innovation <strong>with</strong> potential to benefit patients in unexpected ways.<br />
External Outreach<br />
Key Areas for Dialog and <strong>Partnering</strong><br />
• Emerging technologies that bring<br />
treatments beyond molecules <strong>with</strong> the<br />
potential to impact our pipeline and<br />
prescription medicines business<br />
• Technologies beyond research, including:<br />
• Delivery technologies for biologics,<br />
including formulations, devices, and<br />
molecular targeting approaches<br />
• Patient compliance and health<br />
monitoring technologies<br />
• E-health solutions<br />
• Robust relationships <strong>with</strong> VC community<br />
and their portfolio companies.<br />
• Engaging to contribute a ‘pharma’<br />
perspective on diverse topics such as<br />
business development paradigms or<br />
preferred animal models in the industry<br />
12 External Outreach<br />
13
Dr. Laurie Churchill<br />
Global Licensing<br />
Immunology/Inflammation<br />
Ridgefield, CT , USA<br />
Phone: +1 203 798 4632<br />
Fax: +1 203 837 4632<br />
E-mail: laurie.churchill@<br />
boehringer-ingelheim.com<br />
Ms. Karen Devine<br />
Global Licensing<br />
Immunology/Inflammation<br />
Ridgefield, CT USA<br />
Phone: +1 203 798 5745<br />
Fax: +1 203 837 5745<br />
E-mail: karen.devine@<br />
boehringer-ingelheim.com<br />
Despite advances in treatment, there remains a large unmet medical need for safe and efficacious<br />
treatment of autoimmune diseases. Our drug discovery in these therapeutic areas<br />
places an emphasis on gaining a mechanistic understanding of rheumatoid arthritis, multiple<br />
sclerosis and psoriasis.<br />
We have extensive expertise and experience in innovative research, pre-clinical and clinical<br />
development, as well as formulation and production of both small molecule and protein<br />
therapeutics in autoimmune and inflammatory diseases. We are looking for partners who are<br />
aiming as well to fill therapeutic gaps in these areas.<br />
Immunology/Inflammation<br />
Key Areas for <strong>Partnering</strong><br />
• Rheumatoid arthritis<br />
• Psoriasis<br />
• Multiple sclerosis<br />
Additional <strong>Partnering</strong> Interest<br />
• Inflammatory Bowel Disease (Crohn’s<br />
disease, ulcerative colitis)<br />
• Systemic lupus erythematosus<br />
Excluded Areas<br />
• Prophylactic vaccines<br />
• Antisense<br />
• Gene therapy<br />
14 Immunology/Inflammation<br />
15
Dr. Monica Cheng<br />
Licensing Liaison Infectious Diseases<br />
Ridgefield, CT , USA<br />
Phone: +1 203 798 5268<br />
Fax: +1 203 837 5268<br />
E-mail: monica.cheng@boehringer-ingelheim.com<br />
The success of Viramune®, a product from our own internal research, and Aptivus®, a non-peptidic HIV<br />
protease inhibitor licensed from Pharmacia and Upjohn, have proven our exceptional capabilities in the<br />
research, development and marketing of anti-infective agents, both independently and as a partner.<br />
We continue to seek innovative approaches for the treatment of HIV infection to complement our<br />
existing portfolio of anti-retrovirals.<br />
Although our recent focus has embraced HIV and HCV, we recognize the many other serious unmet<br />
medical needs in the field of infectious diseases. Indeed, we already have discovery projects targeting<br />
many of the indications listed as key areas for partnering, and are seeking to broaden and strengthen our<br />
portfolio in these areas through partnerships and collaborations at all stages of discovery, development<br />
and commercialization.<br />
Infectious Diseases<br />
Key Areas for <strong>Partnering</strong><br />
• Therapeutic approaches to enable<br />
clearance of latent or persistent viral<br />
infections (e.g. HIV and HBV)<br />
• Targets involved in the replication of<br />
human viral pathogens, especially CMV<br />
and respiratory viruses (e.g. rhinovirus,<br />
RSV and influenza)<br />
• Targets involved in the reactivation of<br />
persistent viral infections (e.g. HSV and<br />
JCV)<br />
• Immunomodulators <strong>with</strong> defined MOA<br />
Additional <strong>Partnering</strong> Interest:<br />
• Antimicrobial or other MOAs for treatment<br />
of respiratory infections<br />
Excluded areas:<br />
• Parenteral IFNs<br />
• Prophylactic vaccines<br />
• Generalized immunomodulators<br />
<strong>with</strong>out defined MOA<br />
• Adjunct therapies (cachexia, secondary<br />
infection, etc.)<br />
• siRNA and antisense therapeutics<br />
16 Infectious Diseases<br />
17
Dr. Claude Gimmi<br />
Global Licensing Oncology<br />
Biberach, Germany<br />
Phone: +49 7351 54 94607<br />
Fax: +49 7351 83 94607<br />
E-mail: claude.gimmi@boehringer-ingelheim.com<br />
Recent advances in tumor biology and genome research have widened the scope of innovative<br />
opportunities for the treatment of cancer. New therapies <strong>with</strong> significantly improved treatment<br />
success rates are on the horizon. Our strong focus on front-line research has allowed us to<br />
rapidly build a strong oncology pipeline <strong>with</strong> several compounds in clinical phases I-III for a<br />
variety of cancer types.<br />
We are looking for partners <strong>with</strong> the same passion to seek new and better treatment options<br />
for cancer patients.<br />
Oncology<br />
Key Areas for <strong>Partnering</strong><br />
• Solid and hematologic cancer indications<br />
• Targeted signal transduction inhibitors<br />
(including compounds targeting mitogenic<br />
pathways, pro-apoptotic pathways,<br />
metabolic pathways), inhibitors of tumor<br />
angiogenesis<br />
• Small molecules as well as monoclonal<br />
antibodies and protein therapeutics<br />
• Mechanisms or approaches <strong>with</strong> the<br />
potential to be clearly differentiated bestin-class<br />
or first-in-class therapies<br />
Excluded Areas<br />
• RNAi and antisense<br />
• Gene therapy<br />
• Radio-immunotherapy<br />
• Cellular vaccines<br />
• Viral-mediated approaches<br />
• Adjunct/supportive therapy<br />
18 Oncology<br />
19
Dr. Paola Casarosa<br />
Global Licensing Respiratory<br />
Biberach, Germany<br />
Phone: +49 7351 54 93196<br />
Fax: +49 7351 83 93196<br />
E-mail: paola.casarosa@boehringer-ingelheim.com<br />
Since 1921 we continue to strive for further innovations in the treatment of airway diseases<br />
and ample resources <strong>with</strong>in <strong>Boehringer</strong> <strong>Ingelheim</strong> are dedicated in this field. We have a long<br />
history of successful research, development and marketing in respiratory diseases (e. g. Spiriva®,<br />
Atrovent®, Combivent®). Indeed, we are one of the top four respiratory companies worldwide.<br />
In support of our innovative drugs, our device Respimat® represents a modern new generation<br />
of propellant-free inhalers that combines innovative technology <strong>with</strong> the proven efficacy of<br />
Spiriva® - an important advance for patients <strong>with</strong> chronic obstructive pulmonary disease (COPD).<br />
We aim to further strengthen our existing portfolio of respiratory compounds and devices<br />
through in-licensing and external collaborations.<br />
Respiratory<br />
Key Areas for <strong>Partnering</strong><br />
• Controller drug more effective in COPD<br />
than Steroids<br />
• Treatment and prevention of<br />
exacerbations<br />
• Prevention of remodeling / promotion of<br />
lung repair<br />
• Candidates for combination <strong>with</strong><br />
tiotropium: inhaled, once a day<br />
• Prescription smoking cessation therapies<br />
• Asthma disease modifying therapy<br />
• Controller treatment of severe asthma<br />
• Very safe oral controller treatment for<br />
mild asthma<br />
• Pulmonary and cystic fibrosis<br />
Additional <strong>Partnering</strong> Interest<br />
• Safe, very broad spectrum agents to<br />
increase resistance to infection in the<br />
respiratory tract<br />
• Formulation technologies for inhaled<br />
drugs<br />
• Respiratory tract device technologies<br />
• Approaches to quantifying inflammatory<br />
status, lung repair, exacerbations in trials<br />
• Safe drug to treat pulmonary hypertension<br />
• Disease modifying therapy of rhinitis<br />
Excluded areas<br />
• Drugs targeting mechanisms repeatedly<br />
investigated <strong>with</strong> little or no success<br />
• Gene therapy<br />
20 Respiratory<br />
21
Dr. Shigeto Nagao<br />
Business Development & Licensing Department<br />
Nippon <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Tokyo, Japan<br />
Phone: +81 3 6417 2351<br />
Fax: +81 3 5435 2926<br />
Email: shigeto.nagao@boehringer-ingelheim.com<br />
Dr. Hideyuki Nishiwaki<br />
Business Development & Licensing Department<br />
Nippon <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Tokyo, Japan<br />
Phone: +81 3 6417 2498<br />
Fax: +81 3 5435 2926<br />
Email: hideyuki.nishiwaki@boehringer-ingelheim.com<br />
Contacts for Asia / Japan<br />
Value through Innovation<br />
Nippon <strong>Boehringer</strong> <strong>Ingelheim</strong> was established in 1961. We proactively scout for emerging<br />
partnering opportunities in Asia. The information we receive is immediately passed on to the<br />
relevant therapeutic licensing teams for evaluation or reference. With regular visits and close<br />
interactions <strong>with</strong> companies in Japan, Korea, India, Taiwan and Singapore we can serve as a<br />
regional contact supporting our global partnering activities.<br />
22 Contacts for Asia/Japan<br />
23
Ms. Dianna Qian<br />
Vice President, Business Development<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Shanghai Pharmaceuticals Co., Ltd.<br />
Shanghai, China<br />
Phone: +86 (21) 68639666 1028<br />
Fax: +86 (21) 58780088 06<br />
Email: dianna.qian@boehringer-ingelheim.com<br />
Ms. Mandy Ding<br />
Business Development<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Shanghai Pharmaceuticals Co., Ltd.<br />
Shanghai, China<br />
Phone: +86 (21) 68639666 1030<br />
Fax: +86 (21) 58780088 06<br />
Email: mandy.ding@boehringer-ingelheim.com<br />
Contacts for Asia / China<br />
Value through Innovation<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> established a presence in China in 1995. Our new Business Development<br />
Department was established in 2010 as part of <strong>Boehringer</strong> <strong>Ingelheim</strong> Shanghai Pharmaceuticals.<br />
This department’s mission is two-fold: 1) We are sourcing suitable late stage commercial deal<br />
opportunities for emerging markets, <strong>with</strong> an emphasis on China; and 2) We are a strong local<br />
arm to bring innovation from China to the global <strong>Boehringer</strong> <strong>Ingelheim</strong> organization.<br />
24 Contacts for Asia/China<br />
25
Dr. Stephan Lensky<br />
Head, Strategic Transactions & Alliance Management<br />
<strong>Ingelheim</strong>, Germany<br />
Phone: +49 6132 77 6105<br />
Fax: +49 6132 72 6105<br />
E-mail: stephan.lensky@boehringer-ingelheim.com<br />
Strategic Transactions and Alliance Management<br />
Value through Innovation<br />
The Strategic Transactions and Alliance Management Team structures and negotiates<br />
corporate partnership deals and manages them over the entire life time of the alliance.<br />
26 Strategic Transactions & Alliance Management<br />
27
Strategic Transactions & Alliance Management - North America Strategic Transactions & Alliance Management - North America<br />
Mr. John Adamou<br />
Head, US Strategic Transactions & Alliance Management<br />
Ridgefield, CT, USA<br />
Phone: +1 203 798 4515<br />
Fax: +1 203 837 4515<br />
E-mail: john.adamou@boehringer-ingelheim.com<br />
Mr. J.C. Martignoni<br />
Strategic Transactions & Alliance Management<br />
Ridgefield, CT, USA<br />
Phone: +1 203 798 5154<br />
Fax: +1 203 837 5154<br />
E-mail: jc.martignoni@boehringer-ingelheim.com<br />
Ms. Alexia Priest<br />
Strategic Transactions & Alliance Management<br />
Ridgefield, CT, USA<br />
Phone: +1 203 791 6061<br />
Fax: +1 203 837 6061<br />
E-mail: alexia.priest@boehringer-ingelheim.com<br />
28 Strategic Transactions & Alliance Management<br />
29
Strategic Transactions & Alliance Management - Europe<br />
Mr. Juergen Beck<br />
Strategic Transactions & Alliance Management<br />
<strong>Ingelheim</strong>, Germany<br />
Phone: + 49 6132 77 97137<br />
Fax: + 49 6132 72 97137<br />
E-mail: juergen.beck@boehringer-ingelheim.com<br />
Dr. Angelika Bonin-Debs<br />
Strategic Transactions & Alliance Management<br />
<strong>Ingelheim</strong>, Germany<br />
Phone: +49 6132 77 5271<br />
Fax: +49 6132 72 5271<br />
E-mail: angelika.bonin-debs@boehringer-ingelheim.com<br />
Strategic Transactions & Alliance Management - Europe<br />
Mr. Dieter Kemmer<br />
Strategic Transactions & Alliance Management<br />
<strong>Ingelheim</strong>, Germany<br />
Phone: +49 6132 77 90051<br />
Fax: +49 6132 72 90051<br />
E-mail: dieter.kemmer@boehringer-ingelheim.com<br />
Dr. Gustav F. Trilsbach<br />
Strategic Transactions & Alliance Management<br />
<strong>Ingelheim</strong>, Germany<br />
Phone: +49 6132 77 3406<br />
Fax: +49 6132 72 3406<br />
E-mail: gustav.trilsbach@boehringer-ingelheim.com<br />
30 Strategic Transactions & Alliance Management<br />
31
Strategic Transactions & Alliance Management - Japan/East Asia<br />
Mr. Shin Takaoki<br />
Strategic Transactions & Alliance Management<br />
Nippon <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Tokyo, Japan<br />
Phone: +81 3 6417 2457<br />
Fax: +81 3 5435 2926<br />
Email: shin.takaoki@boehringer-ingelheim.com<br />
32 Strategic Transactions & Alliance Management<br />
33
and you may just observe<br />
Put us under your microscope<br />
what you’ve been looking for!<br />
<strong>Sincerely</strong>, <strong>Yours</strong><br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> GmbH<br />
Binger Strasse 173<br />
55216 <strong>Ingelheim</strong> am Rhein<br />
Germany<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Pharmaceuticals<br />
900 Ridgebury Road<br />
Ridgefield, CT 06877<br />
USA<br />
34 35
www.boehringer-ingelheim.com
Change language